ClinicalTrials.Veeva

Menu

Effect of RhizomK on Testosterone Levels, the Anabolic Response to Exercise and Overall Quality of Life in Physically Active Healthy Males

A

All India Institute of Medical Sciences, Bhubaneswar

Status

Not yet enrolling

Conditions

Adult Healthy Volunteers

Treatments

Other: Plcebo
Drug: RhizomK

Study type

Interventional

Funder types

Other

Identifiers

NCT07143474
T/IM-NF/Pharm/25-26/29

Details and patient eligibility

About

Given that testosterone is a key modulator of muscle protein synthesis and overall anabolic response to resistance training, any natural intervention that boosts testosterone levels could logically contribute to improved exercise performance, lean muscle gain, and subjective vitality. 13 However, despite encouraging preclinical and ethnopharmacological data, clinical validation of Curculigo extract in human participants-especially in the context of exercise and lifestyle enhancement-is lacking. A novel extract of Curculigo orchioides (commercially known as RhizomK™) has been developed. This randomized, double-blind, placebo-controlled study seeks to bridge this crucial gap by evaluating the efficacy and safety of RhizomK™ supplementation in healthy, physically active males. The findings of this study have the potential to substantiate RhizomK™ as a scientifically supported dietary intervention for enhancing hormonal balance, physical performance, and well-being in men who are not candidates for pharmacological therapy but are seeking to optimize their health through lifestyle and supplementation.

Enrollment

60 estimated patients

Sex

Male

Ages

21 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male sex, aged 21 to 40 (inclusive)
  • Currently engaged in, and has been engaged in resistance training
  • (i.e., weightlifting), training three or more times per week for at least
  • the prior 12 months.
  • Healthy subject (no medical conditions that per the PI assessment).
  • No significant past medical history
  • No significant past surgical history that in the opinion of the PI
  • would preclude study participation.
  • Passes the screening with Physical Activity Readiness questionnaire (PAR-Q)
  • Not currently or recently (within the prior eight-weeks) taken a
  • dietary supplement that is purported to increase testosterone
  • levels.
  • Agrees to follow and adhere to the study directions.
  • Agrees that their study visits will be scheduled at a similar time of the day
  • to minimize and potential circadian rhythm impacts.

Exclusion criteria

  • Takes any prescribed medication or over-the-counter medication which is known to affect testosterone levels.
  • Positive medical history of heart disease/cardiovascular disease, high blood pressure (140/90 or greater mmHg), kidney disease, hepatic impairment or disease, or Type I or Type II diabetes or any other medical condition or diagnosis that the PI would deem exclusionary.
  • Positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit.
  • Positive medical history for any gastrointestinal disease or illness Positive history of gastrointestinal surgery that is known to alter or impact the digestion, absorption of nutrients and or fluids (i.e., gastric bypass).
  • History of hospitalization or in-patient or out-patient treatment for alcohol dependence or drug addiction over the past one year.
  • History of hospitalization or in-patient treatment for depression or any mental health related condition within the past one year.
  • Allergic to any of the ingredients in the study product.
  • Subject is unwilling to follow study directions.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

60 participants in 2 patient groups, including a placebo group

Group RhizomK
Experimental group
Treatment:
Drug: RhizomK
Group Placebo
Placebo Comparator group
Treatment:
Other: Plcebo

Trial contacts and locations

1

Loading...

Central trial contact

Debasish Hota, DM; Rituparna Maiti, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems